Overview: Testosterone Total Ultrasensitive TestIntroduction: The Testosterone Total Ultrasensitive Test measures total testosterone to diagnose hypogonadism, causing low energy. Following 2023 AUA guidelines, it uses biochemical methods for high sensitivity, supporting hormonal screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in endocrinology for patients with suspected hypogonadism.
Other Names: Ultrasensitive Testosterone Assay, Total Testosterone Test.
FDA Status: Laboratory-developed test (LDT), meeting endocrinology standards for diagnostic accuracy.
Historical Milestone: Ultrasensitive testosterone testing began in the 1990s with hormonal research. Biochemical methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures total testosterone to diagnose hypogonadism, guides treatment, and evaluates patients with low energy.
Test Parameters: 1. Total Testosterone Level
Pretest Condition: Fasting for 10-12 hours required. Collect serum, plasma, or saliva. Report history of low energy or hypogonadism symptoms.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document low energy, fatigue, or history of hypogonadism. Include current medications, especially testosterone therapy.
Consent: Written consent required, detailing the tests purpose, hypogonadism implications, and risks of sample collection.
Procedural Considerations: Uses high-sensitivity chemiluminescence to measure total testosterone levels. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for hypogonadism diagnosis.
Factors Affecting Result Accuracy: Improper fasting or sample hemolysis can affect results. Medications like anabolic steroids may alter testosterone levels.
Clinical Significance: Low total testosterone confirms hypogonadism, guiding testosterone replacement therapy. Normal levels may require free testosterone or LH testing.
Specialist Consultation: Consult an endocrinologist or urologist for result interpretation and treatment planning.
Additional Supporting Tests: Free testosterone, LH/FSH, or SHBG to confirm hypogonadism diagnosis.
Test Limitations: Non-specific for certain hormonal conditions; clinical correlation is needed. Sample quality affects sensitivity.
References: AUA Testosterone Guidelines, 2023; Journal of Clinical Endocrinology, Matsumoto AM, 2022.
